Clin Mol Hepatol.
2020 Oct;26(4):577-578. 10.3350/cmh.2020.0143.
Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
- Affiliations
-
- 1Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2507976
- DOI: http://doi.org/10.3350/cmh.2020.0143
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Current Status of Systemic Therapy in Hepatocellular Carcinoma
- Current Status of Molecular Targeted Therapies in Hepatocellular Carcinoma
- Newer treatments for advanced hepatocellular carcinoma
- Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
